Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Piroxicam (CP-16171) 是一种非甾体抗炎剂,能够抑制COX 的活性,对人单核细胞 COX-1 和 COX-2 的IC50值分别为 47 和 25 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
500 mg | ¥ 326 | 现货 | ||
1 g | ¥ 395 | 现货 | ||
5 g | ¥ 833 | 现货 | ||
10 g | ¥ 1,467 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 395 | 现货 |
产品描述 | Piroxicam (CP-16171) is a non-specific COX inhibitor. |
靶点活性 | COX-1:47 μM, hμMan monocyte COX-2:25 μM |
体外活性 | Piroxicam induces activation of extracellular signal-regulated kinase (ERK) in neurones and phosphorylation of heavy molecular weight neurofilaments, cytoskeletal substrates of ERK in rat spinal cord cultures. Piroxicam and NS-398 protect neurones against hypoxia/reperfusion in rat spinal cord cultures. [1] |
体内活性 | Piroxicam at doses higher than 0.04%, strongly inhibits the development of GST-P-positive and neoplastic nodules as well as fibrosis, cirrhosis and formation of 8-hydroxydeoxyguanosine (8-OHdG) adducts in rats. [2] Piroxicam increases the expression of all three MHC antigens compared to either control or azoxymethane (AOM)-treated rats. Piroxicam up-regulates colonic MHC antigen expression in the AOM model of colonic carcinogenesis. [3] Piroxicam combined with Cisplatin has antitumor activity against oral malignant melanoma (OMM) and oral squamous cell carcinoma (SCC) in rats. [4] Piroxicam inhibits prostaglandin synthesis through cyclooxygenase blockade in dog, and Piroxicam does not have any direct cytotoxic effects in vitro. [5] Piroxicam also binds strongly to plasma proteins and Piroxicam could stop Ochratoxin A (OTA) -binding and transport into target organs, thereby preventing its nephrotoxicity in rats. Piroxicam prevents the enzymuria induced by OTA and increases renal elimination of OTA in rats. [6] |
别名 | 吡罗昔康, CP-16171 |
分子量 | 331.35 |
分子式 | C15H13N3O4S |
CAS No. | 36322-90-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 1 mg/mL (3.01 mM)
DMSO: 61 mg/mL (184.1 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 3.018 mL | 15.0898 mL | 30.1796 mL | 75.4489 mL |
DMSO | 5 mM | 0.6036 mL | 3.018 mL | 6.0359 mL | 15.0898 mL |
10 mM | 0.3018 mL | 1.509 mL | 3.018 mL | 7.5449 mL | |
20 mM | 0.1509 mL | 0.7545 mL | 1.509 mL | 3.7724 mL | |
50 mM | 0.0604 mL | 0.3018 mL | 0.6036 mL | 1.509 mL | |
100 mM | 0.0302 mL | 0.1509 mL | 0.3018 mL | 0.7545 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Piroxicam 36322-90-4 Immunology/Inflammation Neuroscience COX 吡罗昔康 Cyclooxygenase CP 16171 CP-16171 inhibit CP16171 Inhibitor inhibitor